Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment
暂无分享,去创建一个
Masatoshi Kudo | Ghassan K Abou-Alfa | Franco Trevisani | M. Kudo | G. Abou-Alfa | L. Rimassa | F. Trevisani | Lorenza Rimassa
[1] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[2] M. Levrero,et al. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein , 2001, Oncogene.
[3] R. Groszmann,et al. American association for the study of liver diseases , 1992 .
[4] Ding‐Shinn Chen,et al. Percutaneous Ethanol Injection Versus Surgical Resection for the Treatment of Small Hepatocellular Carcinoma: A Prospective Study , 2005, Annals of surgery.
[5] W. Lau,et al. A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma , 2006, Annals of surgery.
[6] D. Amadori,et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[8] M. Makuuchi,et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. , 2009, Journal of hepatology.
[9] G. Abou-Alfa. Selection of patients with hepatocellular carcinoma for sorafenib. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[10] K. Owzar,et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Pazdur,et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. , 2009, The oncologist.
[12] Surgery or ablation for hepatocellular carcinoma. , 2009, Annals of surgery.
[13] G. Abou-Alfa,et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Yong Zeng,et al. A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria , 2010, Annals of surgery.
[15] D. Amadori,et al. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. , 2011, Gastrointestinal cancer research : GCR.
[16] M. Makuuchi,et al. Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version , 2011, Digestive Diseases.
[17] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[18] M. Kudo. Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy , 2012, Liver Cancer.
[19] C. Porta,et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. , 2012, Journal of hepatology.
[20] C. Verslype,et al. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] V. Mazzaferro,et al. Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib , 2012, Clinical Cancer Research.
[22] Riccardo Lencioni,et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.
[23] V. Mazzaferro,et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .
[24] M. Osman,et al. Sorafenib in Advanced Hepatocellular Carcinoma-Clinical Experience , 2013 .
[25] M. Kudo,et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Kudo,et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Bruno,et al. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[28] J. Bruix,et al. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis , 2013, British Journal of Cancer.
[29] A. Gasbarrini,et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. , 2013, The Lancet. Oncology.
[30] Osamu Matsui,et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. , 2013, Journal of hepatology.
[31] J. Sosman,et al. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors , 2014, Investigational New Drugs.
[32] L. Schwartz,et al. Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. , 2014, Hepatic oncology.
[33] J. Raoul,et al. How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective , 2014, Liver Cancer.
[34] M. Kudo,et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. , 2014, JAMA.
[35] Chih-Hung Hsu,et al. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. , 2014, Journal of hepatology.
[36] M. Kudo,et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis , 2013, International journal of clinical practice.
[37] Y. Imai,et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.
[38] Joon-Oh Park,et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.
[39] Joon-Oh Park,et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated {alpha}-fetoprotein (AFP) from the randomized phase III REACH study. , 2015 .
[40] S. Kawasaki,et al. Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.
[41] F. Izzo,et al. Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC). , 2016 .
[42] C. Porta,et al. Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC). , 2016 .
[43] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.